Insmed's second quarter revenue of $425.5M beats estimates, driven by strong BRINSUPRI sales, leading to raised FY2026 guidance.

Insmed reported second quarter 2026 total revenue of $425.5 million and a net loss of $0.06 per share, significantly beating analyst estimates for both revenue and earnings. The results were driven by a stronger-than-expected commercial launch of BRINSUPRI, which prompted the company to increase its full-year guidance for the drug.

Key Highlights

• BRINSUPRI global revenue reached $309.2 million in the second quarter, representing 49% sequential growth over the first quarter of 2026.
• The company raised its full-year 2026 BRINSUPRI revenue guidance to a range of $1.25 billion to $1.40 billion, up from its previous guidance of at least $1 billion.
• Net loss narrowed substantially to $13.2 million, or $0.06 per share, compared to a net loss of $321.7 million, or $1.70 per share, in the same quarter last year.
• ARIKAYCE global revenue grew 8% year-over-year to $116.3 million, with guidance for 2026 reiterated at $450 million to $470 million.